Skip to main content
Erschienen in:

11.05.2022 | Acute Lymphocytic Leukemias (F El Chaer and M Keng, Section Editors)

Targeting Apoptosis in ALL

verfasst von: Wesley M. Smith, Daniel R. Reed

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

While the treatment of acute lymphoblastic leukemia (ALL) has improved significantly over the last 30 years, the majority of adult patients will have their disease relapse. The BCL-2 gene was initially discovered from follicular lymphoma research; however, the BH3 family of proteins has is emerging to be crucial in patients with ALL due to their reliance on the balance of these pro-apoptotic and anti-apoptotic proteins in the BH3 family. We discuss apoptosis in ALL, the reliance mechanisms, drug development in this space, and areas for future research.

Recent Findings

The first drugs that were developed to inhibit the BCL-2 pathway include both venetoclax (BCL-2 specific inhibitor) and navitoclax (BCL-2, BCL-XL, and BCL-W). These drugs show promise and have obtained complete remissions, minimal residual disease negative status, and have been used as a bridge to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and chronic lymphocytic leukemia. There are multiple ongoing clinical trials looking to assess the use of BCL-2 inhibition with chemotherapy, targeted therapies, and bi-specific T-cell engager therapies not only in both frontline and relapsed refractory ALL but also in consolidation and maintenance phases.

Summary

There is still a large need for improvement of ALL outcomes in adult patients. Research has shown that ALL depends on the BCL-2 family of proteins for cell survival and proliferation. Targeting this pathway with BCL-2 inhibition has led to encouraging results, and future research is aimed at incorporating this targeted therapy into current treatment paradigms.
Literatur
6.
Zurück zum Zitat Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study [published correction appears in J Clin Oncol. 2017 Aug 10;35(23):2722] [published correction appears in J Clin Oncol. 2017 Aug 20;35(24):2856]. J Clin Oncol. 2017;35(16):1795–802. https://doi.org/10.1200/JCO.2016.69.3531.CrossRefPubMed Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study [published correction appears in J Clin Oncol. 2017 Aug 10;35(23):2722] [published correction appears in J Clin Oncol. 2017 Aug 20;35(24):2856]. J Clin Oncol. 2017;35(16):1795–802. https://​doi.​org/​10.​1200/​JCO.​2016.​69.​3531.CrossRefPubMed
15.
Zurück zum Zitat • Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440–53. https://doi.org/10.1158/2159-8290.CD-20-1465. (Phase 1 trial with combination of venetoclax and navitoclax that shows strong response in patients with ALL.)CrossRefPubMed • Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440–53. https://​doi.​org/​10.​1158/​2159-8290.​CD-20-1465. (Phase 1 trial with combination of venetoclax and navitoclax that shows strong response in patients with ALL.)CrossRefPubMed
41.
Zurück zum Zitat Jain N, et al. A multicenter phase I study combining venetoclax with mini-hyper-cvd in older adults with untreated and relapsed/refractory acute lymphoblastic leukemia. Blood. 2019;134:3867.CrossRef Jain N, et al. A multicenter phase I study combining venetoclax with mini-hyper-cvd in older adults with untreated and relapsed/refractory acute lymphoblastic leukemia. Blood. 2019;134:3867.CrossRef
43.
Zurück zum Zitat • Venugopal S, et al. A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2021;138:1239. (Phase 2 study adding venetoclax to lower intensity chemotherapy backbone shows safety and efficacy in Ph-negative ALL.)CrossRef • Venugopal S, et al. A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2021;138:1239. (Phase 2 study adding venetoclax to lower intensity chemotherapy backbone shows safety and efficacy in Ph-negative ALL.)CrossRef
44.
Zurück zum Zitat Zhang Y, Qian JJ, Shen YJ, Hang SJ, Jin J, Zhu HH. The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia [published online ahead of print, 2021 Oct 18]. Ann Hematol. 2021. doi:https://doi.org/10.1007/s00277-021-04699-2 Zhang Y, Qian JJ, Shen YJ, Hang SJ, Jin J, Zhu HH. The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia [published online ahead of print, 2021 Oct 18]. Ann Hematol. 2021. doi:https://​doi.​org/​10.​1007/​s00277-021-04699-2
46.
Zurück zum Zitat • Short NJ, Konopleva M, Kadia T, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96(7):E229–32. https://doi.org/10.1002/ajh.26175. (Chemotherapy-free regimen of ponatinib and venetoclax demonstrates good effect in patients with Ph-positive ALL.)CrossRefPubMed • Short NJ, Konopleva M, Kadia T, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96(7):E229–32. https://​doi.​org/​10.​1002/​ajh.​26175. (Chemotherapy-free regimen of ponatinib and venetoclax demonstrates good effect in patients with Ph-positive ALL.)CrossRefPubMed
48.
Zurück zum Zitat Palmisiano N, et al. Maximal tolerated dose determined for venetoclax in combination with liposomal vincristine in patients with relapsed or refractory Ph-negative T-cell or B-cell acute lymphoblastic leukemia: results of phase 1 portion of ECOG-ACRIN EA9152. Blood. 2021;138:3407.CrossRef Palmisiano N, et al. Maximal tolerated dose determined for venetoclax in combination with liposomal vincristine in patients with relapsed or refractory Ph-negative T-cell or B-cell acute lymphoblastic leukemia: results of phase 1 portion of ECOG-ACRIN EA9152. Blood. 2021;138:3407.CrossRef
58.
Zurück zum Zitat Arora S, et al. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(9):2292–4.CrossRef Arora S, et al. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(9):2292–4.CrossRef
Metadaten
Titel
Targeting Apoptosis in ALL
verfasst von
Wesley M. Smith
Daniel R. Reed
Publikationsdatum
11.05.2022
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 2/2022
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-022-00661-9

Neu im Fachgebiet Onkologie

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Metastasiertes CRC: besser Checkpointhemmer im Doppelpack!

Die Kombination von Nivolumab plus Ipilimumab ist beim metastasierten Kolorektalkarzinom mit MSI-H- oder dMMR klar im Vorteil gegenüber einer Nivolumab-Monotherapie: Das Progressionsrisiko war damit in einer Phase-3-Studie um 38% reduziert.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

Höhere Trefferquoten bei Brustkrebsscreening dank KI?

Künstliche Intelligenz unterstützt bei der Auswertung von Mammografie-Screenings und senkt somit den Arbeitsaufwand für Radiologen. Wie wirken sich diese Technologien auf die Trefferquote und die Falsch-positiv-Rate aus? Das hat jetzt eine Studie aus Schweden untersucht.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.